Monopar Therapeutics
Develops ALXN1840 for Wilson disease and MNPR-101 radiopharmaceuticals for oncology.
Something off on this page? Send us feedback.
Profile
Builds a clinical-stage pipeline around late-stage ALXN1840 for Wilson disease and MNPR-101 radiopharmaceutical programs for solid tumors. With no approved products or revenue in the latest opened filing, execution centers on regulatory work, clinical trials, radioisotope supply, and outside financing.
Develops clinical-stage medicines through licensing and internal work, with ALXN1840 as the dominant near-term program for Wilson disease. The MNPR-101 platform uses a humanized antibody targeting uPAR to carry imaging or therapeutic radioisotopes into solid-tumor programs.
Operations are based in Wilmette, Illinois, and the portfolio is tied mostly to U.S. regulatory and clinical execution. ALXN1840 came from an Alexion/AstraZeneca Rare Disease license, while MNPR-101 traces back to assets contributed at formation.
No approved products or revenue were reported in the latest opened annual filing. The business depends on FDA review of ALXN1840, early oncology trial execution, radioisotope supply, third-party manufacturing and trial providers, and continued financing.
Company facts
Key statistics
Year to date +70.3% · Average volume (30d) 261.8K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 17, 2026 | Morgan Stanley | Reiterate | Overweight | $115 | $130 | |
| Aug 13, 2026 | Barclays | Reiterate | Overweight | $125 | $128 | |
| Aug 13, 2026 | Cantor Fitzgerald | Downgrade | Overweight | Neutral | ||
| Aug 12, 2026 | Cantor Fitzgerald | Downgrade | Overweight | Neutral | $119 | |
| Aug 12, 2026 | BTIG | Reiterate | Buy | $117 | $133 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 12, 2026Q2 FY26 | −$0.64 | −$0.62 | +3.5% | — | — | — | +0.38% |
| Aug 11, 2026Q2 FY26 | −$0.66 | −$0.62 | +5.4% | — | — | — | −1.62% |
| May 14, 2026Q1 FY26 | −$1.06 | −$0.46 | +56.6% | — | — | — | −2.82% |
| Mar 27, 2026Q4 FY25 | −$0.51 | −$0.61 | −19.1% | — | — | — | −1.50% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | |
| Operating income | −$3.2M | −$3.2M | −$4.1M | −$6.2M | −$5.2M | −$6.6M | |
| Net income | −$2.6M | −$2.5M | −$3.4M | −$5.2M | −$3.9M | −$5.3M | |
| Diluted EPS | −$0.38 | −$0.35 | −$0.48 | −$0.78 | −$0.46 | −$0.62 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY21 $0 · FY22 $0 · FY23 $0 · FY24 $0 · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $134.3M · Total debt $107.8K · Total assets $135.0M · Shareholders' equity $130.9M
Dividends
No dividends on record.
Ownership
Shares outstanding 6.70M · Float 4.16M · 62.2% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Janus Henderson Group PLC | 1.32M | 19.67% | 13F | May 18, 2026 |
| Ra Capital Management, L.P. | 667.2K | 9.96% | 13F | May 15, 2026 |
| Hendricks Diane · 10 percent owner | 567.6K | 8.47% | Form 4 | Dec 17, 2025 |
| Ein # | 562.5K | 10.90% | 13D/G | Nov 6, 2024 |
| AstraZeneca PLC | 522.7K | 7.80% | 13G | Feb 6, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 26, 2026 | Kim R. Tsuchimoto | director | −4,090 | $111.39 |
| Aug 25, 2026 | Raymond Anderson | director | −3,788 | $111.65 |
| Aug 26, 2026 | Patrice Rioux | other: Acting Chief Medical Officer | −1 | $111.26 |
| Dec 26, 2025 | Quan Anh Vu | officer: Chief Financial Officer | +1,500 | $69.95 |
| Dec 18, 2025 | Arthur J. Klausner | director | −5,121 | $67.15 |
Peers
- Bausch Health
Markets established Wilson disease chelator therapies
- Novartis (ADR)
Leads approved radioligand oncology with Pluvicto and Lutathera
- Ultragenyx Pharmaceutical
Develops UX701 gene therapy for Wilson disease
- Eton Pharmaceuticals
Commercializes Galzin and develops ET-700 for Wilson disease
- Lantheus
Radiopharmaceutical diagnostics and therapy pipeline peer
- Telix Pharmaceuticals
Develops paired diagnostic and therapeutic radiopharmaceuticals
- Perspective Therapeutics
Clinical-stage alpha radiopharmaceutical oncology platform
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Monopar Therapeutics | $111.89 | −0.44% | $749.6M | — | — | — | — |
| Bausch Health | $6.32 | 0.00% | $2.36B | — | 1.4 | 0.2 | +11.2% |
| Novartis (ADR) | $153.81 | 0.00% | $292.35B | 23.2 | 16.4 | 5.3 | +0.9% |
| Ultragenyx Pharmaceutical | $25.68 | +0.27% | $2.52B | — | — | 3.5 | +28.5% |
| Eton Pharmaceuticals | $59.78 | −0.02% | $1.64B | 155.4 | 34.1 | 15.5 | +98.6% |
| Lantheus | $100.51 | −0.24% | $6.56B | 24.3 | 18.3 | 4.2 | +2.7% |
| Telix Pharmaceuticals | $11.29 | +0.18% | $3.82B | 113.3 | — | 4.0 | +22.8% |
| Perspective Therapeutics | $3.21 | +3.67% | $354.7M | — | — | 969.1 | −72.1% |
| Median | 68.8 | 17.3 | 4.2 | +11.2% |